25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Atara Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyze Atara Biotherapeutics Inc together

I guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Atara Biotherapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Atara Biotherapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-12.13
Expected worth in 1 year
$-23.07
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-10.94
Return On Investment
-139.7%

For what price can you sell your share?

Current Price per Share
$7.83
Expected price per share
$4.965 - $8.24
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Atara Biotherapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$7.83
Intrinsic Value Per Share
$-58.06 - $-29.75
Total Value Per Share
$-70.18 - $-41.88

2.2. Growth of Atara Biotherapeutics Inc (5 min.)




Is Atara Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$90.5m$37m-$136.7m-137.2%

How much money is Atara Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$240.7m-$229.6m-$11.1m-4.6%
Net Profit Margin-3,874.6%-19,979.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Atara Biotherapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#916 / 933

Most Revenue
#228 / 933

Most Profit
#919 / 933

Most Efficient
#801 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Atara Biotherapeutics Inc?

Welcome investor! Atara Biotherapeutics Inc's management wants to use your money to grow the business. In return you get a share of Atara Biotherapeutics Inc.

First you should know what it really means to hold a share of Atara Biotherapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Atara Biotherapeutics Inc is $7.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atara Biotherapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atara Biotherapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-12.13. Based on the TTM, the Book Value Change Per Share is $-2.74 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atara Biotherapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.93-37.5%-41.53-530.4%-0.94-12.0%-9.03-115.3%-5.02-64.1%
Usd Book Value Change Per Share5.9275.6%-2.74-34.9%-0.75-9.6%-0.90-11.4%-0.27-3.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share5.9275.6%-2.74-34.9%-0.75-9.6%-0.90-11.4%-0.27-3.5%
Usd Price Per Share8.13-4.46-2.32-9.18-18.37-
Price to Earnings Ratio-0.69--0.35--0.74--1.58--4.95-
Price-to-Total Gains Ratio1.37--0.75--3.59--7.84--13.21-
Price to Book Ratio-0.67--0.30-7.19-3.49-3.51-
Price-to-Total Gains Ratio1.37--0.75--3.59--7.84--13.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.83
Number of shares127
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.74-0.90
Usd Total Gains Per Share-2.74-0.90
Gains per Quarter (127 shares)-347.42-113.82
Gains per Year (127 shares)-1,389.67-455.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1390-14000-455-465
20-2779-27900-911-920
30-4169-41800-1366-1375
40-5559-55700-1821-1830
50-6948-69600-2276-2285
60-8338-83500-2732-2740
70-9728-97400-3187-3195
80-11117-111300-3642-3650
90-12507-125200-4098-4105
100-13897-139100-4553-4560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.043.00.02.3%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%10.030.00.025.0%12.032.00.027.3%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.041.06.8%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%10.030.00.025.0%12.032.00.027.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--5.921-2.736+146%-0.753+113%-0.896+115%-0.273+105%
Book Value Per Share---12.127-16.118+33%0.185-6668%-0.922-92%3.664-431%
Current Ratio--0.5890.579+2%2.714-78%4.254-86%13.439-96%
Debt To Asset Ratio--1.6341.694-3%0.922+77%0.690+137%0.383+327%
Debt To Equity Ratio----0%9.421-100%2.143-100%1.114-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Enterprise Value---105357420.000-167277513.175+59%152852180.500-169%792377886.465-113%982856381.340-111%
Eps---2.935-41.529+1315%-0.936-68%-9.029+208%-5.022+71%
Ev To Ebitda Ratio--1.3501.554-13%-0.507+138%-2.249+267%-7.425+650%
Ev To Sales Ratio---0.655-4.043+517%110.815-101%infnan%infnan%
Free Cash Flow Per Share---0.534-4.049+658%-0.659+23%-1.361+155%-1.085+103%
Free Cash Flow To Equity Per Share--4.260-1.750+141%-0.580+114%-0.502+112%-0.006+100%
Gross Profit Margin--1.0001.0020%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---29.751--------
Intrinsic Value_10Y_min---58.058--------
Intrinsic Value_1Y_max---4.149--------
Intrinsic Value_1Y_min---6.940--------
Intrinsic Value_3Y_max---11.577--------
Intrinsic Value_3Y_min---20.004--------
Intrinsic Value_5Y_max---17.932--------
Intrinsic Value_5Y_min---32.038--------
Market Cap45098842.500-35%60698580.00029966236.575+103%218161680.500-72%712665086.415-91%823800956.315-93%
Net Profit Margin---0.545-38.746+7008%-199.795+36551%-52.838+9593%-26.419+4746%
Operating Margin---0.516-4.048+684%-127.805+24663%-31.502+6004%-15.751+2952%
Operating Ratio--1.5414.669-67%133.145-99%34.849-96%17.425-91%
Pb Ratio-0.646+4%-0.670-0.303-55%7.191-109%3.495-119%3.508-119%
Pe Ratio-0.667+4%-0.693-0.346-50%-0.741+7%-1.581+128%-4.947+614%
Price Per Share7.830-4%8.1304.459+82%2.318+251%9.184-11%18.369-56%
Price To Free Cash Flow Ratio-3.664+4%-3.804-1.269-67%-1.132-70%-7.398+94%-9.776+157%
Price To Total Gains Ratio1.322-4%1.373-0.751+155%-3.594+362%-7.844+671%-13.214+1062%
Quick Ratio--0.5720.539+6%4.028-86%6.829-92%23.201-98%
Return On Assets---0.154-1.472+859%-1.108+622%-0.621+305%-0.369+140%
Return On Equity----0%-2.8200%-0.7130%-0.4210%
Total Gains Per Share--5.921-2.736+146%-0.753+113%-0.896+115%-0.273+105%
Usd Book Value---90539000.000-99736499.750+10%37054000.000-344%173975500.050-152%224281325.025-140%
Usd Book Value Change Per Share--5.921-2.736+146%-0.753+113%-0.896+115%-0.273+105%
Usd Book Value Per Share---12.127-16.118+33%0.185-6668%-0.922-92%3.664-431%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value---105357420.000-167277513.175+59%152852180.500-169%792377886.465-113%982856381.340-111%
Usd Eps---2.935-41.529+1315%-0.936-68%-9.029+208%-5.022+71%
Usd Free Cash Flow---3989000.000-23713000.000+494%-50166750.000+1158%-49550050.000+1142%-39996825.000+903%
Usd Free Cash Flow Per Share---0.534-4.049+658%-0.659+23%-1.361+155%-1.085+103%
Usd Free Cash Flow To Equity Per Share--4.260-1.750+141%-0.580+114%-0.502+112%-0.006+100%
Usd Market Cap45098842.500-35%60698580.00029966236.575+103%218161680.500-72%712665086.415-91%823800956.315-93%
Usd Price Per Share7.830-4%8.1304.459+82%2.318+251%9.184-11%18.369-56%
Usd Profit---21909000.000-240744500.000+999%-229605250.000+948%-138013550.000+530%-86743450.000+296%
Usd Revenue--40190000.00025109750.000+60%1135500.000+3439%27343250.000+47%13671625.000+194%
Usd Total Gains Per Share--5.921-2.736+146%-0.753+113%-0.896+115%-0.273+105%
 EOD+1 -7MRQTTM+33 -3YOY+21 -175Y+22 -1610Y+22 -16

3.3 Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.667
Price to Book Ratio (EOD)Between0-1-0.646
Net Profit Margin (MRQ)Greater than0-0.545
Operating Margin (MRQ)Greater than0-0.516
Quick Ratio (MRQ)Greater than10.572
Current Ratio (MRQ)Greater than10.589
Debt to Asset Ratio (MRQ)Less than11.634
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.154
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.451
Ma 20Greater thanMa 5013.284
Ma 50Greater thanMa 10012.352
Ma 100Greater thanMa 20010.296
OpenGreater thanClose6.700
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Fundamental data was last updated by Penke on 2025-01-16 13:23:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -54.5% means that $-0.55 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -54.5%. The company is making a huge loss. -2
  • The TTM is -3,874.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-54.5%TTM-3,874.6%+3,820.1%
TTM-3,874.6%YOY-19,979.5%+16,104.9%
TTM-3,874.6%5Y-5,283.8%+1,409.2%
5Y-5,283.8%10Y-2,641.9%-2,641.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-54.5%-104.6%+50.1%
TTM-3,874.6%-216.4%-3,658.2%
YOY-19,979.5%-208.6%-19,770.9%
5Y-5,283.8%-353.9%-4,929.9%
10Y-2,641.9%-488.0%-2,153.9%
4.3.1.2. Return on Assets

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • -15.4% Return on Assets means that Atara Biotherapeutics Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

  • The MRQ is -15.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -147.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-147.2%+131.9%
TTM-147.2%YOY-110.8%-36.5%
TTM-147.2%5Y-62.1%-85.1%
5Y-62.1%10Y-36.9%-25.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-12.7%-2.7%
TTM-147.2%-13.0%-134.2%
YOY-110.8%-12.3%-98.5%
5Y-62.1%-13.7%-48.4%
10Y-36.9%-15.7%-21.2%
4.3.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Atara Biotherapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-282.0%+282.0%
TTM-5Y-71.3%+71.3%
5Y-71.3%10Y-42.1%-29.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.8%+16.8%
TTM--17.8%+17.8%
YOY-282.0%-16.4%-265.6%
5Y-71.3%-20.6%-50.7%
10Y-42.1%-21.2%-20.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Atara Biotherapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Atara Biotherapeutics Inc is operating .

  • Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -51.6% means the company generated $-0.52  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -51.6%. The company is operating very inefficient. -2
  • The TTM is -404.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-51.6%TTM-404.8%+353.2%
TTM-404.8%YOY-12,780.5%+12,375.7%
TTM-404.8%5Y-3,150.2%+2,745.4%
5Y-3,150.2%10Y-1,575.1%-1,575.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.6%-193.6%+142.0%
TTM-404.8%-321.1%-83.7%
YOY-12,780.5%-227.9%-12,552.6%
5Y-3,150.2%-373.0%-2,777.2%
10Y-1,575.1%-506.1%-1,069.0%
4.3.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.54 means that the operating costs are $1.54 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.541. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.669. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.541TTM4.669-3.128
TTM4.669YOY133.145-128.476
TTM4.6695Y34.849-30.180
5Y34.84910Y17.425+17.425
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5412.171-0.630
TTM4.6693.250+1.419
YOY133.1453.231+129.914
5Y34.8494.838+30.011
10Y17.4256.440+10.985
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Atara Biotherapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.59 means the company has $0.59 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.589. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.579. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.589TTM0.579+0.010
TTM0.579YOY2.714-2.135
TTM0.5795Y4.254-3.675
5Y4.25410Y13.439-9.185
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5893.610-3.021
TTM0.5793.850-3.271
YOY2.7144.605-1.891
5Y4.2545.895-1.641
10Y13.4396.178+7.261
4.4.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.57 means the company can pay off $0.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.572. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.539. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.572TTM0.539+0.033
TTM0.539YOY4.028-3.489
TTM0.5395Y6.829-6.290
5Y6.82910Y23.201-16.372
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5723.034-2.462
TTM0.5393.355-2.816
YOY4.0284.297-0.269
5Y6.8295.890+0.939
10Y23.2016.434+16.767
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Atara Biotherapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.63 means that Atara Biotherapeutics Inc assets are financed with 163.4% credit (debt) and the remaining percentage (100% - 163.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.634. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.694. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.634TTM1.694-0.059
TTM1.694YOY0.922+0.772
TTM1.6945Y0.690+1.004
5Y0.69010Y0.383+0.307
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6340.341+1.293
TTM1.6940.343+1.351
YOY0.9220.310+0.612
5Y0.6900.366+0.324
10Y0.3830.385-0.002
4.5.4.2. Debt to Equity Ratio

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY9.421-9.421
TTM-5Y2.143-2.143
5Y2.14310Y1.114+1.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.429-0.429
YOY9.4210.382+9.039
5Y2.1430.439+1.704
10Y1.1140.489+0.625
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.69 means the investor is paying $-0.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.667. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.693. Based on the earnings, the company is expensive. -2
  • The TTM is -0.346. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.667MRQ-0.693+0.026
MRQ-0.693TTM-0.346-0.347
TTM-0.346YOY-0.741+0.396
TTM-0.3465Y-1.581+1.235
5Y-1.58110Y-4.947+3.366
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.667-2.247+1.580
MRQ-0.693-2.693+2.000
TTM-0.346-3.214+2.868
YOY-0.741-3.335+2.594
5Y-1.581-6.368+4.787
10Y-4.947-6.692+1.745
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -3.664. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.804. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.269. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.664MRQ-3.804+0.140
MRQ-3.804TTM-1.269-2.535
TTM-1.269YOY-1.132-0.137
TTM-1.2695Y-7.398+6.129
5Y-7.39810Y-9.776+2.378
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.664-2.993-0.671
MRQ-3.804-3.671-0.133
TTM-1.269-4.037+2.768
YOY-1.132-4.482+3.350
5Y-7.398-8.190+0.792
10Y-9.776-9.383-0.393
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Atara Biotherapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.67 means the investor is paying $-0.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.646. Based on the equity, the company is expensive. -2
  • The MRQ is -0.670. Based on the equity, the company is expensive. -2
  • The TTM is -0.303. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.646MRQ-0.670+0.025
MRQ-0.670TTM-0.303-0.367
TTM-0.303YOY7.191-7.494
TTM-0.3035Y3.495-3.798
5Y3.49510Y3.508-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.6461.933-2.579
MRQ-0.6702.265-2.935
TTM-0.3032.447-2.750
YOY7.1912.454+4.737
5Y3.4953.664-0.169
10Y3.5084.239-0.731
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

4.8.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 50.825% of the shares of Atara Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30EcoR1 Capital, LLC8.14160.13054689386225915.3091
2024-09-30Redmile Group, LLC7.85230.216645227000
2024-09-30Citadel Advisors Llc4.52240.000426048000
2024-09-30Bank of America Corp3.53530.0001203627176169.4704
2024-09-30Vanguard Group Inc3.13750180715113796.7198
2024-09-30Millennium Management LLC3.05660.00071760535938250.897
2024-09-30Vestal Point Capital LP2.16460.07691246771267711.3188
2024-09-30TANG CAPITAL MANAGEMENT LLC1.30550.04377519600
2024-09-30Renaissance Technologies Corp1.1760.0008677342167047.0432
2024-09-30BlackRock Inc1.0583060954-191-0.3124
2024-09-30Geode Capital Management, LLC0.811104672040439.4735
2024-09-30Centiva Capital LP0.75360.00743403-96847-69.0531
2024-09-30Staley Capital Advisers Inc0.69450.01454000000
2024-09-30FMR Inc0.4351025061738141.7477
2024-09-30State Street Corp0.3881022353768052.341
2024-09-30Morgan Stanley - Brokerage Accounts0.2811016189-3381-17.2764
2024-09-30Bridgeway Capital Management, LLC0.24310.00251400000
2024-09-30JPMorgan Chase & Co0.023801370-290-17.4699
2024-09-30Wells Fargo & Co0.021701251936297.1429
2024-09-30Tower Research Capital LLC0.01310.0002752-3715-83.1654
Total 39.61530.49392281743+100599+4.4%

4.9.2. Funds holding Atara Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30Vanguard Total Stock Mkt Idx Inv2.08790.000112025800
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr0.94580.00055447300
2024-11-30Fidelity Extended Market Index0.4360.000725111-166-0.6567
2024-09-30Bridgeway Ultra-Small Company Market0.24310.0651400000
2024-03-31BlackRock Small Cap Index V.I. I0.00730.00221047000
2024-12-31Fidelity Enhanced Small Cap ETF0.18140.01191044800
2024-10-31Fidelity VIP Disciplined Small Cap Init0.16720.0192963100
2024-05-31Nationwide Multi-Cap Portfolio R60.00630.0002906100
2024-11-30Fidelity Total Market Index0.14120.0001813200
2024-12-31Extended Equity Market Fund K0.1320.00077602-105-1.3624
2024-11-30Fidelity Series Total Market Index0.10420.00016002-321-5.0767
2024-10-31T. Rowe Price Extended Equity Market Idx0.0810.0042466400
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.06890.00053967-1-0.0252
2024-09-30NT Ext Equity Mkt Idx Fd - L0.06150.0004354200
2024-09-30Northern Trust Extended Eq Market Idx0.06150.0004354200
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.05550.0005319690.2824
2024-11-30Spartan Extended Market Index Pool E0.05490.000631631665.5389
2024-11-30Vanguard Balanced Index Inv0.04510.0001259500
2024-11-30Spartan Total Market Index Pool E0.04350.0001250700
2024-09-30PGIM Quantitative Solutions US Micro Cap0.04340.2734250025000
Total 4.96770.3809304864+2082+0.7%

5.3. Insider Transactions

Insiders are holding 22.151% of the shares of Atara Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-18Anhco NguyenSELL166411.2
2024-11-18Eric J HyllengrenSELL136411.2
2024-11-18Jill HenrichSELL100011.2
2024-08-16Anhco NguyenSELL18216.63
2024-08-16Eric J HyllengrenSELL10706.63
2024-08-16Pascal TouchonSELL30386.63
2024-05-16Anhco NguyenSELL171515.5
2024-05-16Eric J HyllengrenSELL114515.5
2024-05-16Pascal TouchonSELL326015.5
2024-03-04Anhco NguyenSELL42918
2024-03-04Pascal TouchonSELL99318
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -571367-204149-5541-143622



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets142,706
Total Liabilities233,245
Total Stockholder Equity-90,539
 As reported
Total Liabilities 233,245
Total Stockholder Equity+ -90,539
Total Assets = 142,706

Assets

Total Assets142,706
Total Current Assets91,855
Long-term Assets50,851
Total Current Assets
Cash And Cash Equivalents 46,453
Short-term Investments 20,736
Net Receivables 1,335
Inventory 13,980
Other Current Assets 9,351
Total Current Assets  (as reported)91,855
Total Current Assets  (calculated)91,855
+/-0
Long-term Assets
Property Plant Equipment 47,494
Long-term Assets Other 3,357
Long-term Assets  (as reported)50,851
Long-term Assets  (calculated)50,851
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities155,979
Long-term Liabilities77,266
Total Stockholder Equity-90,539
Total Current Liabilities
Short-term Debt 14,658
Accounts payable 2,146
Other Current Liabilities 22,831
Total Current Liabilities  (as reported)155,979
Total Current Liabilities  (calculated)39,635
+/- 116,344
Long-term Liabilities
Long-term Liabilities  (as reported)77,266
Long-term Liabilities  (calculated)0
+/- 77,266
Total Stockholder Equity
Common Stock1
Retained Earnings -2,041,860
Accumulated Other Comprehensive Income 22
Other Stockholders Equity 1,951,298
Total Stockholder Equity (as reported)-90,539
Total Stockholder Equity (calculated)-90,539
+/-0
Other
Cash and Short Term Investments 67,189
Common Stock Shares Outstanding 7,466
Current Deferred Revenue116,344
Liabilities and Stockholders Equity 142,706
Net Debt 3,448
Net Working Capital -64,124
Short Long Term Debt Total 49,901



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
4,290
0
0
0
51,828
62,866
58,503
54,120
106,122
169,817
161,102
340,379
324,975
312,978
300,814
284,417
263,914
241,738
244,155
229,693
217,779
473,108
492,707
442,940
391,839
324,726
274,144
364,785
342,942
299,547
428,111
405,532
588,120
529,637
456,791
449,923
468,127
397,280
436,121
368,316
376,420
302,083
246,439
188,788
165,504
165,272
117,284
142,706
142,706117,284165,272165,504188,788246,439302,083376,420368,316436,121397,280468,127449,923456,791529,637588,120405,532428,111299,547342,942364,785274,144324,726391,839442,940492,707473,108217,779229,693244,155241,738263,914284,417300,814312,978324,975340,379161,102169,817106,12254,12058,50362,86651,8280004,290
   > Total Current Assets 
0
4,207
0
0
51,808
62,291
57,085
52,022
106,026
169,691
160,634
340,235
324,597
311,741
298,883
282,230
260,553
235,318
222,492
206,217
172,190
413,614
425,070
372,976
321,489
250,830
201,139
293,418
272,992
229,217
358,987
339,432
523,273
464,307
392,325
369,497
384,621
314,389
346,984
283,046
295,080
224,182
172,320
118,696
101,869
106,434
62,410
91,855
91,85562,410106,434101,869118,696172,320224,182295,080283,046346,984314,389384,621369,497392,325464,307523,273339,432358,987229,217272,992293,418201,139250,830321,489372,976425,070413,614172,190206,217222,492235,318260,553282,230298,883311,741324,597340,235160,634169,691106,02652,02257,08562,29151,808004,2070
       Cash And Cash Equivalents 
4,207
-4,207
0
0
51,615
39,754
31,779
25,703
21,897
71,329
26,190
54,466
23,746
22,056
26,356
46,013
47,968
62,430
64,237
60,493
79,223
90,495
103,203
66,028
60,698
56,168
59,159
94,431
74,317
70,203
74,511
62,620
200,404
151,097
123,856
113,209
106,084
101,669
70,688
65,114
92,942
48,741
45,898
64,791
25,987
35,233
31,314
46,453
46,45331,31435,23325,98764,79145,89848,74192,94265,11470,688101,669106,084113,209123,856151,097200,40462,62074,51170,20374,31794,43159,15956,16860,69866,028103,20390,49579,22360,49364,23762,43047,96846,01326,35622,05623,74654,46626,19071,32921,89725,70331,77939,75451,61500-4,2074,207
       Short-term Investments 
0
8,414
0
0
0
22,277
24,719
25,996
82,219
95,367
128,841
279,799
296,736
284,347
268,201
232,134
207,714
168,216
152,659
139,728
86,873
316,826
313,812
298,515
248,933
181,377
130,976
188,491
184,792
144,428
273,201
264,565
300,255
284,064
249,524
244,036
264,984
200,142
260,623
200,290
149,877
156,666
107,744
37,617
25,884
11,152
3,978
20,736
20,7363,97811,15225,88437,617107,744156,666149,877200,290260,623200,142264,984244,036249,524284,064300,255264,565273,201144,428184,792188,491130,976181,377248,933298,515313,812316,82686,873139,728152,659168,216207,714232,134268,201284,347296,736279,799128,84195,36782,21925,99624,71922,2770008,4140
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
1,250
9,610
700
400
986
668
637
249
40,221
397
507
163
34,108
35,834
2,422
1,335
1,3352,42235,83434,10816350739740,2212496376689864007009,6101,250800800000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,586
5,340
7,861
6,591
9,706
16,084
18,749
13,980
13,98018,74916,0849,7066,5917,8615,3401,5860000000000000000000000000000000000000000
   > Long-term Assets 
0
-4,207
0
0
20
575
1,418
2,098
96
126
468
144
378
1,237
1,931
2,187
3,361
6,420
21,663
23,476
45,589
59,494
67,637
69,964
70,350
73,896
73,005
71,367
69,950
70,330
69,124
66,100
64,847
65,330
64,466
80,426
83,506
82,891
89,137
85,270
81,340
77,901
74,119
70,092
63,635
58,838
54,874
50,851
50,85154,87458,83863,63570,09274,11977,90181,34085,27089,13782,89183,50680,42664,46665,33064,84766,10069,12470,33069,95071,36773,00573,89670,35069,96467,63759,49445,58923,47621,6636,4203,3612,1871,9311,237378144468126962,0981,4185752000-4,2070
       Property Plant Equipment 
9
0
0
0
8
8
11
14
48
47
42
46
270
1,148
1,830
2,085
3,259
4,400
20,287
22,176
44,129
58,194
66,075
68,279
68,576
72,160
71,486
69,901
68,183
68,133
66,908
64,023
62,820
63,401
62,577
78,556
79,939
28,042
81,910
78,104
74,322
70,995
67,544
63,803
58,791
54,970
51,265
47,494
47,49451,26554,97058,79163,80367,54470,99574,32278,10481,91028,04279,93978,55662,57763,40162,82064,02366,90868,13368,18369,90171,48672,16068,57668,27966,07558,19444,12922,17620,2874,4003,2592,0851,8301,148270464247481411880009
       Long-term Assets Other 
0
-4,207
0
0
12
567
1,407
2,084
48
79
426
98
108
89
101
102
102
2,020
1,376
1,300
1,460
1,300
1,562
1,685
1,774
1,736
1,519
1,466
1,767
2,197
2,216
2,077
2,027
729
689
670
2,367
53,649
7,227
7,166
7,018
6,906
6,575
6,289
4,844
3,868
3,609
3,357
3,3573,6093,8684,8446,2896,5756,9067,0187,1667,22753,6492,3676706897292,0272,0772,2162,1971,7671,4661,5191,7361,7741,6851,5621,3001,4601,3001,3762,020102102101891089842679482,0841,4075671200-4,2070
> Total Liabilities 
1,306
0
0
0
62,845
77,570
2,280
77,149
2,940
3,723
11,847
6,631
9,875
9,144
10,569
14,215
10,178
8,604
23,011
23,737
39,915
33,924
40,208
39,886
52,982
40,792
41,865
46,343
52,161
46,725
46,986
51,597
125,781
130,600
125,253
139,782
188,513
172,964
178,642
181,203
249,780
237,123
238,985
239,626
264,735
263,580
228,152
233,245
233,245228,152263,580264,735239,626238,985237,123249,780181,203178,642172,964188,513139,782125,253130,600125,78151,59746,98646,72552,16146,34341,86540,79252,98239,88640,20833,92439,91523,73723,0118,60410,17814,21510,5699,1449,8756,63111,8473,7232,94077,1492,28077,57062,8450001,306
   > Total Current Liabilities 
1,302
0
0
0
1,524
2,788
2,101
2,412
2,724
3,514
11,644
6,450
9,709
8,860
10,006
13,688
9,675
7,805
11,481
16,516
27,646
21,049
27,234
27,000
39,979
25,175
25,803
30,706
36,743
31,520
31,684
36,055
82,901
84,194
88,830
86,150
105,786
101,562
65,688
72,244
78,916
67,876
74,552
79,089
142,226
180,690
148,267
155,979
155,979148,267180,690142,22679,08974,55267,87678,91672,24465,688101,562105,78686,15088,83084,19482,90136,05531,68431,52036,74330,70625,80325,17539,97927,00027,23421,04927,64616,51611,4817,8059,67513,68810,0068,8609,7096,45011,6443,5142,7242,4122,1012,7881,5240001,302
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
1,581
0
0
0
1,985
23,441
28,194
29,114
2,753
0
31,442
837
13,640
12,610
12,954
13,296
12,179
14,032
13,999
14,658
14,65813,99914,03212,17913,29612,95412,61013,64083731,44202,75329,11428,19423,4411,9850001,581006430010,30010,30050000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000006430010,30010,30050000000000000000000000
       Accounts payable 
121
0
0
0
606
1,402
577
569
440
794
1,703
1,853
1,445
1,896
3,235
4,463
2,778
2,204
5,243
5,539
14,711
6,098
6,545
6,193
3,719
6,168
6,420
5,155
7,963
8,079
5,106
5,190
7,118
17,355
12,301
16,543
17,368
11,945
12,799
11,296
6,871
5,068
4,138
6,511
3,684
2,854
5,253
2,146
2,1465,2532,8543,6846,5114,1385,0686,87111,29612,79911,94517,36816,54312,30117,3557,1185,1905,1068,0797,9635,1556,4206,1683,7196,1936,5456,09814,7115,5395,2432,2042,7784,4633,2351,8961,4451,8531,7037944405695771,402606000121
       Other Current Liabilities 
1,174
0
0
0
918
1,386
1,524
1,843
2,284
2,720
9,941
4,597
8,264
6,964
6,771
9,225
6,897
5,601
6,238
10,977
12,935
14,951
20,689
20,807
36,260
19,007
19,383
25,551
5,733
23,441
26,578
30,865
40,343
7,901
7,367
9,267
44,905
38,674
51,218
57,449
50,405
40,274
45,511
47,671
48,530
40,650
21,433
22,831
22,83121,43340,65048,53047,67145,51140,27450,40557,44951,21838,67444,9059,2677,3677,90140,34330,86526,57823,4415,73325,55119,38319,00736,26020,80720,68914,95112,93510,9776,2385,6016,8979,2256,7716,9648,2644,5979,9412,7202,2841,8431,5241,3869180001,174
   > Long-term Liabilities 
0
0
0
0
61,321
74,782
179
74,737
216
209
203
181
166
284
563
527
503
799
11,530
7,221
12,269
12,875
12,974
12,886
13,003
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
36,423
53,632
82,727
71,402
112,954
108,959
170,864
169,247
164,433
160,537
122,509
82,890
79,885
77,266
77,26679,88582,890122,509160,537164,433169,247170,864108,959112,95471,40282,72753,63236,42346,40642,88015,54215,30215,20515,41815,63716,06215,61713,00312,88612,97412,87512,2697,22111,53079950352756328416618120320921674,73717974,78261,3210000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
141
85
244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000244851411960000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-500
-10,300
-10,300
0
0
13,794
14,919
14,532
14,136
13,809
13,420
13,129
13,041
-10,872
-16,012
-4,540
22,765
17,453
32,557
60,235
58,064
42,308
51,754
48,508
45,693
42,197
38,703
-14,658
-14,65838,70342,19745,69348,50851,75442,30858,06460,23532,55717,45322,765-4,540-16,012-10,87213,04113,12913,42013,80914,13614,53214,91913,79400-10,300-10,300-50000000000000000000000
       Warrants
0
0
0
0
0
0
0
149,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000149,1440000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
165
216
209
203
181
0
0
0
0
0
0
0
0
0
0
0
0
0
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
1,771
53,632
1,501
71,402
5,626
108,959
170,864
169,247
164,433
4,848
39,254
39,974
40,615
0
040,61539,97439,2544,848164,433169,247170,864108,9595,62671,4021,50153,6321,77146,40642,88015,54215,30215,20515,41815,63716,06215,61700000000000001812032092161650000000
> Total Stockholder Equity
2,984
2,984
0
0
-11,017
-14,704
56,223
-23,029
103,182
166,094
149,255
333,748
315,100
303,834
290,245
270,202
253,736
233,134
221,144
205,956
177,864
439,184
452,499
403,054
338,857
283,934
232,279
318,442
290,781
252,822
381,125
353,935
462,339
399,037
331,538
310,141
279,614
224,316
257,479
187,113
126,640
64,960
7,454
-50,838
-99,231
-98,308
-110,868
-90,539
-90,539-110,868-98,308-99,231-50,8387,45464,960126,640187,113257,479224,316279,614310,141331,538399,037462,339353,935381,125252,822290,781318,442232,279283,934338,857403,054452,499439,184177,864205,956221,144233,134253,736270,202290,245303,834315,100333,748149,255166,094103,182-23,02956,223-14,704-11,017002,9842,984
   Common Stock
1
0
0
0
1
0
1
-19,909
2
2
2
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5
5
5
6
6
7
8
8
8
8
9
9
9
9
9
10
10
10
10
11
12
0
1
1012111010101099999888876655555543333333333222-19,9091010001
   Retained Earnings Total Equity00000-1,838,903-1,767,795-1,693,024-1,618,452-1,534,361-1,552,827-1,464,722-1,371,373-1,286,709-1,202,916-1,124,581-1,043,274-968,926-891,470-817,961-739,465-667,570-593,242-527,349-447,337-388,976-338,093-296,650-261,337-230,241-202,813-177,159-158,924-133,551-114,671-98,110-76,862-64,994-50,049-40,889-30,3620000000
   Accumulated Other Comprehensive Income 
0
-3,727
0
0
-335
-11
0
-11
-100
-18
-66
51
-518
51
193
35
-183
-152
-114
-88
-151
-524
-505
-449
-340
38
173
233
220
204
810
527
296
161
62
24
-368
-1,892
-2,618
-2,959
-2,067
-1,237
-933
-571
-204
-55
-14
22
22-14-55-204-571-933-1,237-2,067-2,959-2,618-1,892-368246216129652781020422023317338-340-449-505-524-151-88-114-152-1833519351-51851-66-18-100-110-11-33500-3,7270
   Capital Surplus 
0
0
0
0
0
0
0
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
0
0
0
0
0
000001,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,3440000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-58,891
-69,333
84,477
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721
1,833,982
1,847,280
1,858,423
1,870,112
1,902,637
1,909,097
1,951,298
1,951,2981,909,0971,902,6371,870,1121,858,4231,847,2801,833,9821,821,7211,808,5151,794,4491,779,0261,744,6951,681,4811,618,1771,601,7841,586,6161,396,6741,349,2341,144,0821,108,5161,057,669899,671877,133866,541850,835841,975777,797474,662467,378451,496436,096431,075429,088423,600418,451413,725410,556214,313216,159144,1697,34484,477-69,333-58,8910000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.